Hepatic Expression of the Serine Palmitoyltransferase Subunit Sptlc2 Reduces Lipid Droplets in the Liver by Activating VLDL Secretion
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: Ceramide is a signaling molecule that contributes to insulin resistance and hepatosteatosis. In the present study, we activated de novo ceramide synthesis by inducing the hepatic expression of Sptlc2 to investigate the role of ceramide in glucose and lipid metabolism. Methods: We first constructed an adenovirus containing Sptlc2 (AdSptlc2), which encodes a major catalytic subunit of serine palmitoyltransferase (SPT). We then infected hepatocytes and mice fed a regular diet with AdSptlc2 to activate de novo ceramide biosynthesis. The liver-specific effects of ceramide biosynthesis on glucose and lipid metabolism were investigated by measuring changes in insulin signaling, lipid droplet formation, and very low-density lipoprotein (VLDL) secretion. Results: In HepG2 hepatocytes, adenoviral Sptlc2 expression inhibited insulin signaling and increased ceramide levels via activation of c-Jun N-terminal kinase and serine phosphorylation of insulin receptor substrate 1. In contrast, in mice, AdSptlc2 infection decreased plasma glucose levels by downregulating gluconeogenic genes and increased plasma triglyceride levels by increasing VLDL secretion. In mice infected with AdSptlc2, glucose intolerance and insulin sensitivity improved, while pyruvate utilization via gluconeogenesis decreased. Conclusion: Hepatic ceramide was found to modulate hepatosteatosis and the insulin response via increased VLDL secretion and inhibition of gluconeogenesis in vivo. Although inhibition of the insulin response was observed in vitro, the compensatory mechanism of relieving ceramide-induced stress and reducing ceramide levels resulted in improvements of glucose and lipid metabolic profiles in vivo. This discrepancy between in vitro and in vivo regulation mechanisms suggests that ceramide plays a role in non-alcoholic fatty liver disease and insulin resistance.
Abstract
Objective: Ceramide is a signaling molecule that contributes to insulin resistance and hepatosteatosis. In the present study, we activated de novo ceramide synthesis by inducing the hepatic expression of Sptlc2 to investigate the role of ceramide in glucose and lipid metabolism. Methods: We first constructed an adenovirus containing Sptlc2 (AdSptlc2), which encodes a major catalytic subunit of serine palmitoyltransferase (SPT). We then infected hepatocytes and mice fed a regular diet with AdSptlc2 to activate de novo ceramide biosynthesis. The liver-specific effects of ceramide biosynthesis on glucose and lipid metabolism were investigated by measuring changes in insulin signaling, lipid droplet formation, and very low-density lipoprotein (VLDL) secretion. Results: In HepG2 hepatocytes, adenoviral Sptlc2 expression inhibited insulin signaling and increased ceramide levels via activation of c-Jun N-terminal kinase and serine phosphorylation of insulin receptor substrate 1. In contrast, in mice, AdSptlc2 infection decreased plasma glucose levels by downregulating gluconeogenic genes and increased plasma triglyceride levels by increasing VLDL secretion. In mice infected with AdSptlc2, glucose intolerance and insulin sensitivity improved, while pyruvate utilization via gluconeogenesis decreased. Conclusion: Hepatic ceramide was found to modulate hepatosteatosis and the insulin response via increased VLDL secretion and inhibition of gluconeogenesis in vivo. Although inhibition of the insulin response was observed in vitro, the compensatory mechanism of relieving ceramide-induced stress and reducing ceramide levels resulted in improvements of glucose and lipid metabolic profiles in vivo. This discrepancy between in vitro and in vivo regulation mechanisms suggests that ceramide plays a role in non-alcoholic fatty liver disease and insulin resistance.
참고문헌 (35)
- Barr EL, "HOMA insulin sensitivity index and the risk of all-cause mortality and cardiovascular disease events in the general population : the Australian Diabetes, Obesity and Lifestyle Study(AusDiab)study", Diabetologia, 53, pp.79~88 (2010)
- Hastie CE, "Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention", Eur Heart J, 31, pp.222~226 (2010)
- Roberts AW, "Review article : left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease--do we need to screen our patients?", Diab Vasc Dis Res, 6, pp.153~163 (2009)
- Bradbury MW, "Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake : possible role in steatosis", Am J Physiol Gastrointest Liver Physiol, 290, pp.G194~G198 (2006)
- Unger RH, "Lipid overload and overflow : metabolic trauma and the metabolic syndrome", Trends Endocrinol Metab, 14, pp.398~403 (2003)
- Listenberger LL, "Triglyceride accumulation protects against fatty acid-induced lipotoxicity", Proc Natl Acad Sci U S A, 100, pp.3077~3082 (2003)
- Jaeschke A, "Metabolic stress signaling mediated by mixed-lineage kinases", Mol Cell, 27, pp.498~508 (2007)
- Jeong T, "Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase", J Clin Invest, 101, pp.905~912 (1998)
- Hanada K, "Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism", Biochim Biophys Acta, 1632, pp.16~30 (2003)
- Weiss B, "Human and murine serine-palmitoyl-CoA transferase--cloning, expression and characterization of the key enzyme in sphingolipid synthesis", Eur J Biochem, 249, pp.239~247 (1997)
- Hojjati MR, "Serine palmitoyl-CoA transferase(SPT)deficiency and sphingolipid levels in mice", Biochim Biophys Acta, 1737, pp.44~51 (2005)
- Li Z, "Liver-specific deficiency of serine palmitoyltransferase subunit 2 decreases plasma sphingomyelin and increases apolipoprotein E levels", J Biol Chem, 284, pp.27010~27019 (2009)
- Hornemann T, "Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase", J Biol Chem, 281, pp.37275~37281 (2006)
- Hornemann T, "Is the mammalian serine palmitoyltransferase a high-molecular-mass complex?", Biochem J, 405, pp.157~164 (2007)
- Stratford S, "Regulation of insulin action by ceramide : dual mechanisms linking ceramide accumulation to the inhibition of Akt", protein kinase B, 2004, pp.279, 36608~36615
- Holland WL, "Sphingolipids, insulin resistance, and metabolic disease : new insights from in vivo manipulation of sphingolipid metabolism", Endocr Rev, 29, pp.381~402 (2008)
- Park TS, "Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice", Circulation, 110, pp.3465~3471 (2004)
- Holland WL, "Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance", Cell Metab, 5, pp.167~179 (2007)
- Park TS, "Ceramide is a cardiotoxin in lipotoxic cardiomyopathy", J Lipid Res, 49, pp.2101~2112 (2008)
- Cheng GC, "Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells", Exp Cell Res, 300, pp.297~307 (2004)
- He TC, "A simplified system for generating recombinant adenoviruses", Proc Natl Acad Sci U S A, 95, pp.2509~2514 (1998)
- Duffy AM, "Purification of adenovirus and adeno-associated virus : comparison of novel membrane-based technology to conventional techniques", Gene Ther, 12(Suppl 1), pp.S62~S72 (2005)
- Chang ZQ, "Endotoxin activates de novo sphingolipid biosynthesis via nuclear factor kappa B-mediated upregulation of Sptlc2", Prostaglandins Other Lipid Mediat, 94, pp.44~52 (2011)
- Yoo HH, "Liquid chromatography-tandem mass spectrometric determination of ceramides and related lipid species in cellular extracts", J Chromatogr B Analyt Technol Biomed Life Sci, 843, pp.327~333 (2006)
- Ryu D, "TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1", Cell Metab, 9, pp.240~251 (2009)
- Hotamisligil GS, "Endoplasmic reticulum stress and the inflammatory basis of metabolic disease", Cell, 140, pp.900~917 (2010)
- Chaurasia B, "Targeting a ceramide double bond improves insulin resistance and hepatic steatosis", Science, 365, pp.386~392 (2019)
- Pettus BJ, "Ceramide in apoptosis : an overview and current perspectives", Biochim Biophys Acta, 1585, pp.114~125 (2002)
- Oskouian B, "Cancer treatment strategies targeting sphingolipid metabolism", Adv Exp Med Biol, 688, pp.185~205 (2010)
- Bartke N, "Bioactive sphingolipids : metabolism and function", J Lipid Res, 50(Suppl), pp.S91~S96 (2009)
- Ussher JR, "Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption", Diabetes, 59, pp.2453~2464 (2010)
- Li Z, "Reducing plasma membrane sphingomyelin increases insulin sensitivity", Mol Cell Biol, 31, pp.4205~4218 (2011)
- Hirosumi J, "A central role for JNK in obesity and insulin resistance", Nature, 420, pp.333~336 (2002)
- Morad SA, "Ceramide-orchestrated signalling in cancer cells", Nat Rev Cancer, 13, pp.51~65 (2013)
- Jiang M, "Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty liver disease", Front Endocrinol(Lausanne), 10, pp.665~ (2019)